Instrument Inactif

Communiqués AgeX Therapeutics, Inc.

Actions

AGE

US00848H2076

Communiqués

22/03/24	AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results	AQ
27/02/24	AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE	BU
28/12/23	AgeX Therapeutics : New Financial Obligation - Form 8-K	PU
01/12/23	AgeX Therapeutics : Termination of Material Agreement - Form 8-K	PU
14/11/23	AgeX Therapeutics Reports Third Quarter 2023 Financial Results	BU
06/10/23	AgeX Therapeutics : New Financial Obligation - Form 8-K	PU
06/09/23	AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE	BU
30/08/23	Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement	BU
25/08/23	AgeX Therapeutics : New Financial Obligation - Form 8-K	PU
14/08/23	AgeX Therapeutics Reports Second Quarter 2023 Financial Results	BU
25/07/23	AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock	BU
24/07/23	AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock	AQ
21/07/23	AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock	BU
08/06/23	AGEX THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	AQ
23/05/23	AgeX Therapeutics Announces Appeal of NYSE American Determination	BU
15/05/23	AgeX Therapeutics Reports First Quarter 2023 Financial Results	AQ
12/05/23	AgeX Therapeutics Reports First Quarter 2023 Financial Results	BU
26/04/23	AGEX THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)	AQ
26/04/23	AgeX Therapeutics Receives Stock Exchange Deficiency Letter	BU
06/04/23	AGEX THERAPEUTICS, INC. : Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	AQ
31/03/23	AGEX THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
31/03/23	AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results	BU
15/03/23	AGEX THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
17/02/23	AGEX THERAPEUTICS, INC. : Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	AQ
10/02/23	AGEX THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ